Edgar Filing: CORCEPT THERAPEUTICS INC - Form 4

CORCEPT THERAPEUTICS INC

Form 4

February 23, 2005

FORM 4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
	Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0287

Expires:

January 31, 2005

Estimated average burden hours per

response...

0.5

if no longer subject to Section 16. Form 4 or Form 5

obligations

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

may continue. See Instruction

1(b).

(Last)

(City)

(Print or Type Responses)

1. Name and Address of Reporting Person * BELANOFF JOSEPH K

2. Issuer Name and Ticker or Trading Symbol

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

(Check all applicable)

Chief Executive Officer

5. Relationship of Reporting Person(s) to

Issuer

below)

CORCEPT THERAPEUTICS INC [CORT]

(Middle)

(Zip)

3. Date of Earliest Transaction

(Month/Day/Year) 02/18/2005

X Director X_ Officer (give title

X__ 10% Owner _ Other (specify

C/O CORCEPT THERAPEUTICS **INCORPORATED, 275** MIDDLEFIELD ROAD

(Street)

(State)

(First)

4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

Person

MENLO PARK, CA 94025

(City)	(State)	Tab	le I - Non-	Derivativ	e Secu	rities Acq	uired, Disposed o	f, or Beneficia	ılly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securities Acquired on(A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or Amount (D) Price		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	02/18/2005		S(2)	2,500	D	\$ 4.4948	2,366,695	D	
Common Stock							300,000	I	Custodian for minor son (1)
Common Stock							300,000	I	Custodian for minor daughter (1)
Common	02/22/2005		S(2)	2,500	D	\$ 4.47	2,364,195	D	

Edgar Filing: CORCEPT THERAPEUTICS INC - Form 4

Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

of

9. Nu Deriv

Bene Own Follo Repo Trans (Instr

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Titl Amou Under Securi (Instr.	nt of lying	8. Price of Derivative Security (Instr. 5)
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	

Reporting Owners

Reporting Owner Name / Address		Relationships					
1 6	Director	10% Owner	Officer	Other			
BELANOFF JOSEPH K							
C/O CORCEPT THERAPEUTICS INCORPORATED		X	Chief Executive Officer				
275 MIDDLEFIELD ROAD	Λ	Λ	Chief Executive Officer				
MENLO PARK, CA 94025							

Signatures

s/s Fred Kurland, CFO of Corcept Therapeutics Incorporated attorney-in-fact

02/23/2005

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Reporting Person is the custodian for minor children and disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein.
- (2) The sale on this Form 4 was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 15, 2004. Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Reporting Owners 2

Edgar Filing: CORCEPT THERAPEUTICS INC - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.